JP2002531409A - アジスロマイシンのエタノール付加物、その製造方法、及びその医薬製剤 - Google Patents
アジスロマイシンのエタノール付加物、その製造方法、及びその医薬製剤Info
- Publication number
- JP2002531409A JP2002531409A JP2000584898A JP2000584898A JP2002531409A JP 2002531409 A JP2002531409 A JP 2002531409A JP 2000584898 A JP2000584898 A JP 2000584898A JP 2000584898 A JP2000584898 A JP 2000584898A JP 2002531409 A JP2002531409 A JP 2002531409A
- Authority
- JP
- Japan
- Prior art keywords
- azithromycin
- ethanol
- adduct
- ethanol adduct
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 93
- 229960004099 azithromycin Drugs 0.000 title claims abstract description 43
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 43
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 239000013078 crystal Substances 0.000 claims abstract description 5
- 239000000725 suspension Substances 0.000 claims description 12
- 238000002425 crystallisation Methods 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 6
- HQUPLSLYZHKKQT-WVVFQGGUSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-o Chemical compound O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 HQUPLSLYZHKKQT-WVVFQGGUSA-N 0.000 description 3
- 229960003256 azithromycin monohydrate Drugs 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 238000003109 Karl Fischer titration Methods 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 229930006677 Erythromycin A Natural products 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000012052 hydrophilic carrier Substances 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11029898P | 1998-11-30 | 1998-11-30 | |
| US60/110,298 | 1998-11-30 | ||
| PCT/US1999/028368 WO2000032203A1 (en) | 1998-11-30 | 1999-11-30 | Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002531409A true JP2002531409A (ja) | 2002-09-24 |
| JP2002531409A5 JP2002531409A5 (enExample) | 2005-12-22 |
Family
ID=22332273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000584898A Pending JP2002531409A (ja) | 1998-11-30 | 1999-11-30 | アジスロマイシンのエタノール付加物、その製造方法、及びその医薬製剤 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6365574B2 (enExample) |
| EP (2) | EP1484062A1 (enExample) |
| JP (1) | JP2002531409A (enExample) |
| KR (1) | KR100603226B1 (enExample) |
| CN (2) | CN100339384C (enExample) |
| AP (1) | AP1709A (enExample) |
| AT (1) | ATE279200T1 (enExample) |
| AU (1) | AU768219B2 (enExample) |
| BG (1) | BG105547A (enExample) |
| CA (1) | CA2352562A1 (enExample) |
| CZ (1) | CZ20011886A3 (enExample) |
| DE (1) | DE69921192T2 (enExample) |
| DK (1) | DK1152765T3 (enExample) |
| ES (1) | ES2229804T3 (enExample) |
| HK (1) | HK1043725B (enExample) |
| HU (1) | HUP0104241A3 (enExample) |
| IL (1) | IL143376A0 (enExample) |
| LV (1) | LV12735B (enExample) |
| NZ (1) | NZ512496A (enExample) |
| PL (1) | PL197894B1 (enExample) |
| PT (1) | PT1152765E (enExample) |
| RO (1) | RO121408B1 (enExample) |
| RU (1) | RU2240124C2 (enExample) |
| SI (1) | SI20639A (enExample) |
| WO (1) | WO2000032203A1 (enExample) |
| ZA (1) | ZA200104312B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20020231A2 (en) * | 2002-03-18 | 2003-12-31 | Pliva D D | ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A |
| TW546302B (en) * | 1998-05-08 | 2003-08-11 | Biochemie Sa | Improvements in macrolide production |
| CA2245398C (en) | 1998-08-21 | 2002-01-29 | Apotex Inc. | Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof |
| HK1043725B (en) * | 1998-11-30 | 2005-05-06 | Teva Pharmaceutical Industries Ltd. | Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof |
| JP2004519430A (ja) * | 2000-11-27 | 2004-07-02 | バイオケミ・エセ・ア | マクロライドの溶媒和物 |
| CN100341886C (zh) * | 2000-11-27 | 2007-10-10 | 桑多斯股份公司 | 大环内酯类化合物的溶剂化物 |
| KR100431431B1 (ko) * | 2001-04-25 | 2004-05-14 | 한미약품 주식회사 | 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물 |
| HUP0400446A2 (hu) * | 2001-05-22 | 2004-09-28 | Pfizer Products Inc. | Azitromicin kristályformái |
| US6861413B2 (en) * | 2001-05-22 | 2005-03-01 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
| EP1671978A1 (en) * | 2001-05-22 | 2006-06-21 | Pfizer Products Inc. | New Cristal Form of Azithromycin |
| EP1541134A3 (en) * | 2001-10-18 | 2007-06-06 | Teva Pharmaceutical Industries Limited | Stabilized azithromycin compositions |
| EP1446010B1 (en) | 2001-10-18 | 2009-04-15 | Teva Pharmaceutical Industries Ltd. | Stabilized azithromycin compositions |
| US20080149521A9 (en) * | 2001-10-18 | 2008-06-26 | Michael Pesachovich | Methods of stabilizing azithromycin |
| IL161259A0 (en) * | 2001-12-21 | 2004-09-27 | Pfizer Prod Inc | Methods for wet granulating azithromycin |
| WO2003053416A1 (en) * | 2001-12-21 | 2003-07-03 | Pfizer Products Inc. | Directly compressible formulations of azithromycin |
| PL372394A1 (en) * | 2002-02-01 | 2005-07-25 | Pfizer Products Inc. | Dry granulated formulations of azithromycin |
| HRP20020614A2 (en) * | 2002-07-22 | 2004-06-30 | PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. | Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a |
| US20050013835A1 (en) * | 2003-07-15 | 2005-01-20 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
| US20050101547A1 (en) * | 2003-11-06 | 2005-05-12 | Sadatrezaei Mohsen | Stabilized azithromycin composition |
| WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
| US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| JP2007513147A (ja) * | 2003-12-04 | 2007-05-24 | ファイザー・プロダクツ・インク | 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法 |
| CA2547597A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
| DE602004014805D1 (de) * | 2003-12-04 | 2008-08-14 | Pfizer Prod Inc | Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten |
| CN1889933A (zh) * | 2003-12-04 | 2007-01-03 | 辉瑞产品公司 | 由基于液体的工艺制备的阿奇霉素多颗粒剂型 |
| WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
| US7943585B2 (en) | 2003-12-22 | 2011-05-17 | Sandoz, Inc. | Extended release antibiotic composition |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| US7683162B2 (en) * | 2004-08-30 | 2010-03-23 | Taro Pharmaceutical Industries Limited | Process of preparing a crystalline azithromycin monohydrate |
| CA2591744A1 (en) * | 2004-12-21 | 2006-06-29 | Pfizer Products Inc. | Stable non-dihydrate azithromycin oral suspensions |
| US20060198895A1 (en) * | 2005-03-07 | 2006-09-07 | Kotliar Eleonora M | Azithromycin powder for oral suspension compositions |
| US20090318375A1 (en) * | 2005-06-08 | 2009-12-24 | Hanmi Pharm Co., Ltd | Crystalline Azithromycin L-Malate Monohydrate and Pharmaceutical Composition Containing Same |
| US9433516B2 (en) * | 2007-04-17 | 2016-09-06 | Micell Technologies, Inc. | Stents having controlled elution |
| JP2012520268A (ja) | 2009-03-13 | 2012-09-06 | ダ・ボルテラ | グラム陰性細菌の除去のための組成物及び方法 |
| WO2013088274A1 (en) | 2011-12-14 | 2013-06-20 | Wockhardt Limited | Anhydrous amorphous azithromycin composition free of azithromycin dihydrate |
| CN103983730B (zh) * | 2014-06-11 | 2015-09-30 | 北京市药品检验所 | 阿奇霉素或其制剂中的杂质检查方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU43006B (en) | 1981-03-06 | 1989-02-28 | Pliva Pharm & Chem Works | Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof |
| US4474768A (en) | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| RO107257B1 (ro) | 1987-07-09 | 1993-10-30 | Pfizer | Procedeu de obtinere a unui dihidrat de azitromicina, cristalin |
| WO1989002271A1 (en) * | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
| CN1093370A (zh) | 1993-12-10 | 1994-10-12 | 北京市集才药物研究所 | 一种新的阿齐红霉素结晶及其制备方法 |
| CN1161971A (zh) * | 1997-01-03 | 1997-10-15 | 石家庄制药集团有限公司 | 一种阿齐霉素结晶及其制备方法 |
| CA2245398C (en) * | 1998-08-21 | 2002-01-29 | Apotex Inc. | Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof |
| HK1043725B (en) * | 1998-11-30 | 2005-05-06 | Teva Pharmaceutical Industries Ltd. | Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof |
| KR100491183B1 (ko) * | 2001-03-21 | 2005-05-25 | 한미약품 주식회사 | 아지트로마이신의 제조방법 및 이 방법에 사용되는9-데옥소-9에이-아자-9에이-호모에리트로마이신 에이의결정성 수화물 |
| HUP0400446A2 (hu) * | 2001-05-22 | 2004-09-28 | Pfizer Products Inc. | Azitromicin kristályformái |
-
1999
- 1999-11-30 HK HK02102775.5A patent/HK1043725B/en not_active IP Right Cessation
- 1999-11-30 AU AU31065/00A patent/AU768219B2/en not_active Ceased
- 1999-11-30 CN CNB2005100785525A patent/CN100339384C/zh not_active Expired - Fee Related
- 1999-11-30 CA CA002352562A patent/CA2352562A1/en not_active Abandoned
- 1999-11-30 NZ NZ512496A patent/NZ512496A/xx unknown
- 1999-11-30 DE DE69921192T patent/DE69921192T2/de not_active Expired - Fee Related
- 1999-11-30 RO ROA200100573A patent/RO121408B1/ro unknown
- 1999-11-30 WO PCT/US1999/028368 patent/WO2000032203A1/en not_active Ceased
- 1999-11-30 RU RU2001118035/15A patent/RU2240124C2/ru not_active IP Right Cessation
- 1999-11-30 KR KR1020017006669A patent/KR100603226B1/ko not_active Expired - Fee Related
- 1999-11-30 DK DK99965069T patent/DK1152765T3/da active
- 1999-11-30 EP EP04014455A patent/EP1484062A1/en not_active Withdrawn
- 1999-11-30 PT PT99965069T patent/PT1152765E/pt unknown
- 1999-11-30 ES ES99965069T patent/ES2229804T3/es not_active Expired - Lifetime
- 1999-11-30 CN CNB998158542A patent/CN1273142C/zh not_active Expired - Fee Related
- 1999-11-30 EP EP99965069A patent/EP1152765B1/en not_active Expired - Lifetime
- 1999-11-30 AP APAP/P/2001/002183A patent/AP1709A/en active
- 1999-11-30 PL PL347971A patent/PL197894B1/pl not_active IP Right Cessation
- 1999-11-30 IL IL14337699A patent/IL143376A0/xx unknown
- 1999-11-30 US US09/451,738 patent/US6365574B2/en not_active Expired - Lifetime
- 1999-11-30 AT AT99965069T patent/ATE279200T1/de not_active IP Right Cessation
- 1999-11-30 HU HU0104241A patent/HUP0104241A3/hu unknown
- 1999-11-30 JP JP2000584898A patent/JP2002531409A/ja active Pending
- 1999-11-30 SI SI9920086A patent/SI20639A/sl not_active IP Right Cessation
- 1999-11-30 CZ CZ20011886A patent/CZ20011886A3/cs unknown
-
2001
- 2001-05-25 ZA ZA200104312A patent/ZA200104312B/en unknown
- 2001-05-29 BG BG105547A patent/BG105547A/xx unknown
- 2001-06-22 LV LVP-01-79A patent/LV12735B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002531409A (ja) | アジスロマイシンのエタノール付加物、その製造方法、及びその医薬製剤 | |
| WO2000032203A9 (en) | Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof | |
| US20090131665A1 (en) | Process for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCI | |
| EP2454238A1 (en) | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide | |
| JP2003534310A (ja) | 塩酸セルトラリンの新規な非結晶形態 | |
| JP2005523874A (ja) | Ｎ−〔３−（３−シアノピラゾロ〔１，５−ａ〕ピリミジン−７−イル）フェニル〕−Ｎ−エチルアセタミド（ザレプロン）の精製方法、及び当該方法により得られうるザレプロンの結晶型 | |
| CN111004255A (zh) | 一种头孢卡品内酯化合物或其盐酸盐的制备方法 | |
| CN116041351B (zh) | 盐酸咪达唑仑新晶型及其制备方法 | |
| CN115160186A (zh) | 氨基甲酸苯酯晶型及其制备方法 | |
| JP2002532510A (ja) | クラリスロマイシンの製造に於けるマクロライド中間体 | |
| EP1741704A1 (en) | Method for increasing specific surface area of slightly soluble drug | |
| JP2002506002A (ja) | ４，５−エポキシモルフィナン−６−オール類のグリコシド化 | |
| CN111094313A (zh) | 盐酸伊达比星一水合物的晶型 | |
| CN110903291B (zh) | 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法 | |
| KR880001235B1 (ko) | 결정성 무수 소듐 19-데옥시아글리콘 디아네마이신의 제조 방법 | |
| EP1813602A1 (en) | Crystal of two-ring heterocyclic sulfonamide compound | |
| AU2022412842A1 (en) | Novel acid addition salt and crystalline form of (2r,3s)-2-(3-(4,5-dichloro-1h-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol | |
| WO2022081502A1 (en) | Solid state forms of lorecivivint | |
| JP2003505485A (ja) | フォームｉセリプロロールヒドロクロリドの改良形態 | |
| CN119968365A (zh) | 依那格列净的新晶型及其制备方法 | |
| CN117425651A (zh) | Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途 | |
| JP2002511485A (ja) | 結晶形態の１Ｓ−［１α（２Ｓ＊，３Ｒ＊），９α］−６，１０−ジオキソ−Ｎ−（２−エトキシ−５−オキソテトラヒドロ−３−フラニル）−９−［［（１−イソキノリル）カルボニル］アミノ］オクタヒドロ−６Ｈ−ピリダジノ［１，２−Ａ］［１，２］ジアゼピン−１−カルボキサミド | |
| JP2003515579A (ja) | 高純度デフェロキサミン・メシレート塩の製造のための多段階プロセス | |
| JPWO1998031683A1 (ja) | 新規ｚ−バラシクロビル結晶 | |
| HK1117160A1 (en) | Crystals of laquinimod sodium, and process for the manufacture thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040820 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040820 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080422 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080930 |